Profile: Abbott Laboratories (ABT)
24 Oct 2014
Abbott Laboratories (Abbott), incorporated on March 6, 1900, is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.
The products include a line of diagnostic systems and tests manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites, and plasma protein therapeutic companies. The principal products included in the diagnostic products segment are immunoassay and clinical chemistry systems, including ARCHITECT and ABBOTT PRISM; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases, such as hepatitis and HIV; the m2000, an instrument that automates the extraction, purification, and preparation of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from patient samples, and detects and measures infectious agents including human immunodeficiency virus (HIV), hepatitis B virus ( HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and computed tomography (CT)/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit, the UroVysion bladder cancer recurrence kit,and the Vysis ALK Break Apart FISH Probe Kit, the non-small-cell lung cancer therapy XALKORI; informatics and automation solutions for use in the laboratory; a l line of hematology systems and reagents known as the Cell-Dyn series, and the i-STAT point-of-care diagnostic systems and tests for blood analysis.
In addition, under a distribution agreement with Celera Group, the diagnostic products segment distributes certain Celera molecular diagnostic products, including the ViroSeq HIV genotyping system and products used for the detection of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which causes cystic fibrosis. The segment's products are generally marketed and sold directly from Abbott-owned distribution centers, public warehouses and third-party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.
The products include a line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide. The principal products included in the nutritional products segment are various forms of prepared infant formula and follow-on formula, including Similac Advance, Similac Advance with EarlyShield, Similac, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Similac Go&Grow, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Isomil Advance, Isomil, Alimentum, Gain, and Grow; adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Muscle Health, Ensure (with Nutrivigor), Glucerna, Glucerna Hunger Smart, ProSure, PediaSure, PediaSure Sidekicks, EleCare, Juven, Abound, and Pedialyte; nutritional products used in enteral feeding in health care institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa,
Freego (Enteral Pump) and Freego sets, and Nepro, and Zone Perfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge.
In addition, certain nutritional products sold as Gain, Grow, PediaSure, PediaSure Sidekicks, Pedialyte, Ensure, Zone Perfect, EAS/Myoplex, and Glucerna are also promoted directly to the public by consumer marketing efforts in select markets. These products are marketed and sold directly to customers and to institutions, wholesalers, retailers, health care facilities, government agencies, and third-party distributors from Abbott-owned distribution centers or third-party distributors.
The products include a line of coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease manufactured, marketed and sold worldwide. The segment's products are generally marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.
The principal products included in the vascular products segment are Xience Xpedition, Xience Prime, Xience nano, and Xience V, drug-eluting coronary stent systems developed on the Multi-Link Vision platform; Absorb, a drug-eluting coronary bioresorbable vascular scaffold; Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, coronary metallic stents; TREK and Voyager, coronary balloon dilatation products; Hi-Torque Balance Middleweight Elite and ASAHI coronary guidewires (licensed from Asahi Intecc Co., Ltd.); StarClose and Perclose vessel closure devices; Acculink/Accunet and Xact/Emboshield NAV, carotid stent systems; Armada and Absolute Pro Peripheral balloon dilatation products; Herculink Elite Renal and Omnilink Elite Iliac stent systems, and MitraClip, a percutaneous valve repair system.
The principal products in Abbott's other businesses include blood glucose monitoring meters, test strips, data management software and accessories for people with diabetes, including the FreeStyle product line, and medical devices for the eye, including cataract surgery, laser-assisted in situ keratomileusis (LASIK) surgery, contact lens care products, and dry eye products. These products are marketed worldwide and sold directly to wholesalers, government agencies, health care facilities, mail order pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Some of these products are marketed and distributed through distributors. Blood glucose monitoring meters, contact lens care products, and dry eye products are also marketed and sold over-the-counter to consumers.
C/O TAX DEPT D367 & AP6D
100 Abbott Park Road
ABBOTT PARK IL 60064-3500
Company Web Links
- Factbox: Another U.S. tax 'inversion' implodes, pending deals dwindle
- Abbott, Mylan silent on why changing tax-inversion terms
- UPDATE 2-Abbott, Mylan silent on why changing tax-inversion terms
- Abbott, Mylan back generics deal, tweak terms after tax rule change
- Abbott says third-quarter sales match forecasts